Increasing unusual option volume: WKHS ZYNE HIMX BGCP INVH MT ELF
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
UPDATE: Needham & Company Downgrades Zynerba Pharmaceuticals (ZYNE) to Hold
July 1, 2020 7:18 AM EDT(Updated - July 1, 2020 7:22 AM EDT)
(updating comment)
Needham & Company analyst Serge Belanger downgraded Zynerba Pharmaceuticals (NASDAQ: ZYNE) from Buy to Hold.
The analyst comments "Zygel missed primary and secondary endpoints in the pivotal ph 3 CONNECT-FX trial, but met the... More
